Issue:October 2012

FORMULATION DEVELOPMENT – Recombinant Human Albumin: Delivering the Future of Type 2 Diabetes Medication


INTRODUCTION

The number of people with diabetes is expected to rise to approximately 300 million by the year 2030; of this number, some 90% will have the type 2, noninsulin dependent form of the disease.1 The major goal in the treatment of type II diabetes is to achieve and maintain glycaemic control as episodes of hyperglycaemia are associated with the risk of microvascular and macrovascular complications.2 Treatment for type 2 diabetes is typically incremental, starting with the modification of diet and introduction of exercise followed by the introduction of an orally active diabetic medication.3 Despite the wide range of available oral medications, many patients fail to achieve appropriate glycaemic control and will ultimately require the introduction of injectable insulin. A particular focus area of research for the treatment of type 2 diabetes is the development of alternative and supportive therapies to oral diabetic agents that reduce the need for the introduction of insulin. In particular, analogues of the natural GLP-1 peptide have become an important class of molecules in this area.3

GLP-1 is a 30 amino acid peptide that belongs to the incretin family. It is secreted in direct response to the ingestion of food and acts to both stimulate insulin secretion and decrease glucagon production, providing an effective mechanism for glycaemic control. In addition, the peptide also acts to increase satiety and decrease gasticic emptying, which in turn, lead to moderate weight loss. Taken together, these factors have led to considerable interest in using this molecule as an anti-diabetic therapeutic.4

A half-life of native GLP-1 is around 2 minutes; a significant issue when considering this molecule as a therapeutic. The short half-life of GLP-1 is caused by specific clearance by a peptidase enzyme (DPP-4) and by renal clearance due to its relatively small size. The therapeutics that have reached the market or are currently achieving success in the clinic are based on GLP-1 analogues or mimics that have been designed to overcome the issues observed for the native GLP-1 molecule.2 These can be divided into short- and long-acting and a summary of these is detailed in Table 1.

A common feature in the advances in dosing regimen made by Liraglutide (short-acting), Albiglutide, and CJC-1134 (long-acting) is the utilization of the extended plasma half-life of human serum albumin to achieve an extended therapeutic half-life. Here, we discuss the application of human serum albumin as a half-life extension technology for GLP-1 therapeutics and how further developments in recombinant human albumin technology may further change the dosing paradigm.

GLP-1 HALF-LIFE EXTENSION USING HUMAN SERUM ALBUMIN

Human serum albumin is the most abundant plasma protein that has a number of interesting physic-chemical properties that can be used in a pharmaceutical in context. In particular, it has been demonstrated that therapeutic candidates can be attached to the protein and can take advantage of the naturally extended half-life (~19 days) of this protein to avoid rapid clearance from the body.4

Liraglutide, the short-acting GLP-1 analogue, was the first of the GLP-1 analogues to reach the market using human serum albumin as a half-life extension technology. This molecule contained a short fatty acid “tag” attached to glutamic acid at position 26 on the peptide. Once in the plasma, this “tag” can reversibly associate with fatty acid binding sites on circulating human serum albumin, preventing rapid renal clearance. This peptide had a half-life of around 11 to 15 hours and was the first oncedaily treatment using a GLP-1 peptide.5

The next generation of GLP-1 medicaments are targeting once-weekly dosing to both improve patient compliance and efficacy of the therapy. In the context of albumin-based therapeutics, this concept has been demonstrated in the clinic by both GSK’s Albiglutide (Phase III) and Conjuchem’s CJC- 1134 (Phase II). These products use a covalent attachment of the GLP-1 peptide to the albumin molecule and achieve significant increase in half-life compared with the in vivo association used by Liraglutide. This covalent attachment of the therapeutic target is achieved by either genetic fusion or chemical conjugation of the peptide to the albumin.

GlaxoSmithkline’s, Albiglutide, was developed in collaboration with Human Genome Sciences and uses albumin fusion technology licensed from Novozymes Biopharma. The process of albumin fusion involves the insertion of a contiguous piece of DNA that encodes for both the albumin and the GLP-1 peptide into a yeast-based expression system. Using this technology, a functional protein is expressed that has both the properties of albumin and the GLP-1 peptide.6

In contrast, Conjuchem’s CJC-1134 is an engineered GLP-1 peptide, synthesised with an albumin binding group attached to a short linker molecule from the N-terminus of the peptide. This albumin binding group is then reacted with the free cysteine residue on the albumin molecule to form the conjugate.

Despite these two methods of attachment being technically very different in terms of the product design, they both achieve very similar results clinically in terms of half-life and efficacy. The decision of whether to a chose a fusion or conjugation route can be based on many different factors, and both the albumin fusion and conjugates have their own benefits. For example, CJC-1134 uses a peptide containing a non-natural amino acid and would not be amenable to a fusion route using the existing technology.

NEXT GENERATION OF ALBUMIN-BASED ANTI-DIABETIC THERAPEUTICS

As treatment of type 2 diabetes with GLP-1 analogues and other peptide drugs develops, and the notion of longer-acting formulations becomes more accepted by both the regulatory authorities and patients, it is likely the future goals for diabetic treatments will shift further to monthly treatments and beyond. To meet these changing market demands, Novozymes Biopharma is developing the next generation of recombinant albumins for half-life extension. To understand how these molecules are designed, it’s worth taking a look at how the half-life of albumin is regulated.

The half-life of albumin is mediated in part by its size, but also its pH- dependant interaction in the endosome with the FcRn receptor. A schematic of this process is illustrated in Figure 1. Plasma proteins are taken up by vascular endothelial cells through non-specific pinocytosis. As the endosome is formed and the internal pH falls, albumin binds to the FcRn receptor. The albumin that is bound to this receptor is rescued from intracellular degradation, is taken back to the surface of the cell, and released back into the circulation. The FcRn recycling system is saturated, and as a consequence, not all albumins contained within any endosome will be recycled. If the albumin lost to intracellular degradation is also that which has the therapeutic molecule attached, then this will also be degraded. It was considered that an understanding of the interaction between albumin and FcRn and the impact of this process and albumins half-lives may ultimately lead to the ability to design therapeutics with a designed half-life.

Novozymes Biopharma, in collaboration with scientists at the University of Oslo, have identified specific regions within the structure of the albumin molecule that are important for albumin FcRn binding.7 Subsequently, numerous albumin variants have been generated with single amino acid substitutions that display both increased and decreased inding to the FcRn receptor. A number of the variants have been tested in in animal PK studies in which a correlation between FcRn binding affinity and albumin half-life has been established. In particular, one high affinity variant demonstrated double the halflife of native sequence human serum albumin in rodent models. Ultimately, these changes in albumin half-life will translate to the therapeutic target and allow the drug development scientist to control the half-life of a target protein. In the context of GLP-1 peptides, this technology could allow the shift from weekly to every 2 weeks to monthly dosing. To maintain the full flexibility of the application of this technology, Novozymes has applied its extensive experience in recombinant albumin manufacture to ensure this technology is available to albumin fusion and conjugation applications.

SUMMARY

GLP-1 analogues have become an important class of therapeutics in the treatment of type 2 diabetes, offering an alternative therapy to oral diabetic medications that have failed. A major factor in the translation of this peptide from an undrugable natural peptide to successful therapeutics is the application of human serum albumin as a carrier molecule. In particular, the development and expected launch of Albigluitde, the first commercial albumin fusion therapeutic will only further enhance the growing pedigree of this technology. The success with GLP-1 is likely to open the door of the technology to be applied with other therapeutic candidates in the anti-diabetic field.

To ensure albumin half-life extension technology continues to meet the demands of innovative drug design, Novozymes has developed the next generation of albumin half-life extension technology. These albumin “variants” will open the door to longer dosing regimens for peptides such as GLP-1. u

REFERENCES

1. Verspohl VJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev. 2012;64:188- 237.
2. Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, Holland MC, Gutierrez M, Stewart MW. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long acting glucagon-like peptide 1 mimetic, in healthy subjects. Diabet Obes Metab. 2009;11:498-505.
3. Efendic S, Alvarsson M, Brismar K, Wagner H. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs. Acta Physiologica. 2008;192:117-125.
4. Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilising human serum albumin. Pharmaceut Res. 2002;19:569-577.
5. Knudsen LB. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract. (Supplement). 2010;167:4-11.
6. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor dependant pathways coupled with satiety, gastrointestinal motility and glucose homeostasis. Diabet. 2004;53:2492- 2500.
7. Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, O’Brennan S, Gunnarsen KS, Bjoras M, Slee D, Sandlie I. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nature Comm. 2012;3(3):610.

Dr. Mark Perkins is a Customer Solution Manager with a PhD in Pharmaceutical Sciences from the University of Nottingham. He joined Novozymes Biopharma in 2010 as a Customer Solution Specialist. Within this role, he works with partners who are evaluating Novozymes recombinant albumin products and associated technologies in the areas of biopharmaceutical formulation and half-life extension. Prior to this position, Dr. Perkins worked as a Materials Specialist at an inhaled drug development company and as a Project Manager within an analytical consultancy. He can be reached at mrpk@novozymes.com.